Zentera Therapeutics has been spun off by oncology therapy developer Zentalis Pharmaceuticals with a series A round led by Tybourne Capital Management.
US-listed small molecule drug developer Zentalis Pharmaceuticals has spun off a China-based subsidiary called Zentera Therapeutics with $20m in series A funding.
The round was led by investment manager Tybourne Capital Management and backed by OrbiMed Asia, a fund managed by healthcare-focused investment firm OrbiMed. Zentalis retains a majority stake in Zentera.
Zentalis focuses on small molecule cancer drugs, and Zentera was established to prepare at least three of its product candidates for the Chinese market, including Zn-c5, a prospective…
